Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from t
2 days ago
- #avatrombopag
- #immune thrombocytopenia
- #treatment switching
- Patients with primary immune thrombocytopenia (ITP) who switched from eltrombopag or romiplostim to avatrombopag achieved high platelet response rates.
- Most common reason for discontinuing previous therapies (eltrombopag or romiplostim) was lack of efficacy (59.2%).
- Among patients with low baseline platelet counts (<30 × 109/L), 98.7% achieved platelets ≥30 × 109/L and 94.9% achieved ≥50 × 109/L on avatrombopag.
- Response durability on avatrombopag was high: median rates of 93.8% for ≥30 × 109/L, 89.6% for ≥50 × 109/L, and 67.4% for ≥100 × 109/L thresholds.
- The study, REAL-AVA 3.5, concluded that switching to avatrombopag resulted in clinically meaningful and durable platelet responses for most patients.